Steven L. Gonias
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Steven L. Gonias has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Elisabetta Mantuano
Department of Life Sciences, Health, and Health Professions, Link Campus University, 00165 Rome, Italy
16 shared publications - Pardis Azmoon
Department of Pathology, University of California San Diego School of Medicine, La Jolla, California, USA
13 shared publications Alban Gaultier
Department of Neurosciences, University of Virginia School of Medicine, Charlottesville, Virginia
10 shared publicationsMinji Jo
Department of Pathology, University of California San Diego School of Medicine, La Jolla, California
8 shared publicationsW. Marie Campana
Department of Anesthesiology, University of California San Diego, La Jolla, CA 92093, USA The Program in Neuroscience, University of California San Diego, La Jolla, CA 92093, USA
8 shared publications- Michael A. Banki
Department of Pathology, University of California San Diego, La Jolla CA 92093, USA
7 shared publications
Latest Publications
- Open Access
- 5 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110561
The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma
- 5 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110561
Open AccessThe urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma
- Open Access
- 11 January 2024
- Published by Elsevier in Academic Pathology
- Vol. 11 (1) , 100101
Establishing priorities for implementation of large language models in pathology and laboratory medicine
- 11 January 2024
- Published by Elsevier in Academic Pathology
- Vol. 11 (1) , 100101
Open AccessEstablishing priorities for implementation of large language models in pathology and laboratory medicine
- Open Access
LRP1 Triggers Pro-inflammatory Cell-signaling in Response to Extracellular Tau Independently of the NMDA Receptor
In Alzheimer’s Disease (AD) and other neurodegenerative diseases, microtubule-associated protein Tau forms abnormal intracellular aggregates. The mechanisms by which Tau may promote AD progression remain incompletely understood. Injured and dying neurons release Tau into the extracellular spaces in the CNS. The released Tau may be taken up by receptors in the LDL Receptor gene family, including Low Density Lipoprotein Receptor-related Protein-1 (LRP1), which is expressed by microglia, astrocytes, and neurons. This process may be important for clearing Tau from extracellular spaces but may also promote the seeding of Tau aggregates in new cells. Our laboratory has shown that endocytosis of LRP1 ligands is coupled to the activation of cell-signaling and regulation of inflammation. Notably, different LRP1 ligands can induce either pro-inflammatory or anti-inflammatory responses, depending on the co-receptors that function with LRP1. Here, we demonstrate that in cultured macrophages, microglia, and astrocytes, extracellular Tau induces an LRP1-dependent pro-inflammatory response, characterized by NFκB activation and expression of pro-inflammatory cytokines. Unlike other LRP1 ligands that elicit anti-inflammatory responses, the response to Tau occurs independently of the NMDA receptor. When LRP1 is deleted or silenced, macrophages, microglia, and astrocytes do not respond to Tau, whereas when Grin1 is deleted or the NMDA-R is pharmacologically inhibited, the responses remain unchanged. Because we have evidence that LRP1 in microglia expresses anti-inflammatory activity in response to ligands other than Tau, understanding the role of LRP1 in microglia and astrocytes in vivo in Alzheimer’s Disease and other neuroinflammatory processes is an important future goal. SIGNIFICANCE STATEMENT: In Alzheimer’s Disease and other neurodegenerative diseases, microtubule-associated protein Tau forms abnormal intracellular aggregates that contribute to disease progression. When released extracellularly, Tau binds to the transmembrane receptor LRP1, expressed by diverse cells in the CNS. LRP1 has the unique ability to couple ligand uptake with activation of cell-signaling. We demonstrated that Tau binding to LRP1 activates pro-inflammatory responses in macrophages, microglia, and astrocytes, characterized by NFκB activation and cytokine release. This signaling occurs independently of the NMDA receptor, which distinguishes Tau from other LRP1 ligands. These results define a novel pathway by which extracellular Tau regulates neuroinflammation in Alzheimer’s Disease, providing new therapeutic opportunities that target LRP1 without interfering with NMDA-R functions.
Open AccessLRP1 Triggers Pro-inflammatory Cell-signaling in Response to Extracellular Tau Independently of the NMDA Receptor
In Alzheimer’s Disease (AD) and other neurodegenerative diseases, microtubule-associated protein Tau forms abnormal intracellular aggregates. The mechanisms by which Tau may promote AD progression remain incompletely understood. Injured and dying neurons release Tau into the extracellular spaces in the CNS. The released Tau may be taken up by receptors in the LDL Receptor gene family, including Low Density Lipoprotein Receptor-related Protein-1 (LRP1), which is expressed by microglia, astrocytes, and neurons. This process may be important for clearing Tau from extracellular spaces but may also promote the seeding of Tau aggregates in new cells. Our laboratory has shown that endocytosis of LRP1 ligands is coupled to the activation of cell-signaling and regulation of inflammation. Notably, different LRP1 ligands can induce either pro-inflammatory or anti-inflammatory responses, depending on the co-receptors that function with LRP1. Here, we demonstrate that in cultured macrophages, microglia, and astrocytes, extracellular Tau induces an LRP1-dependent pro-inflammatory response, characterized by NFκB activation and expression of pro-inflammatory cytokines. Unlike other LRP1 ligands that elicit anti-inflammatory responses, the response to Tau occurs independently of the NMDA receptor. When LRP1 is deleted or silenced, macrophages, microglia, and astrocytes do not respond to Tau, whereas when Grin1 is deleted or the NMDA-R is pharmacologically inhibited, the responses remain unchanged. Because we have evidence that LRP1 in microglia expresses anti-inflammatory activity in response to ligands other than Tau, understanding the role of LRP1 in microglia and astrocytes in vivo in Alzheimer’s Disease and other neuroinflammatory processes is an important future goal. SIGNIFICANCE STATEMENT: In Alzheimer’s Disease and other neurodegenerative diseases, microtubule-associated protein Tau forms abnormal intracellular aggregates that contribute to disease progression. When released extracellularly, Tau binds to the transmembrane receptor LRP1, expressed by diverse cells in the CNS. LRP1 has the unique ability to couple ligand uptake with activation of cell-signaling. We demonstrated that Tau binding to LRP1 activates pro-inflammatory responses in macrophages, microglia, and astrocytes, characterized by NFκB activation and cytokine release. This signaling occurs independently of the NMDA receptor, which distinguishes Tau from other LRP1 ligands. These results define a novel pathway by which extracellular Tau regulates neuroinflammation in Alzheimer’s Disease, providing new therapeutic opportunities that target LRP1 without interfering with NMDA-R functions.
- Open Access
- 8 August 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (15)
An LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein
Low-density lipoprotein receptor-related protein-1 (LRP1) functions as a receptor for nonpathogenic cellular prion protein (PrP C ), which is released from cells by ADAM (a disintegrin and metalloproteinase domain) proteases or in extracellular vesicles. This interaction activates cell signaling and attenuates inflammatory responses. We screened 14-mer PrP C -derived peptides and identified a putative LRP1 recognition motif in the PrP C sequence spanning residues 98–111. A synthetic peptide (P3) corresponding to this region replicated the cell-signaling and biological activities of full-length shed PrP C . P3 blocked LPS-elicited cytokine expression in macrophages and microglia and rescued the heightened sensitivity to LPS in mice in which the PrP C gene ( Prnp ) had been deleted. P3 activated ERK1/2 and induced neurite outgrowth in PC12 cells. The response to P3 required LRP1 and the NMDA receptor and was blocked by the PrP C -specific antibody, POM2. P3 has Lys residues, which are typically necessary for LRP1 binding. Converting Lys 100 and Lys 103 into Ala eliminated the activity of P3, suggesting that these residues are essential in the LRP1-binding motif. A P3 derivative in which Lys 105 and Lys 109 were converted into Ala retained activity. We conclude that the biological activities of shed PrP C , attributed to interaction with LRP1, are retained in synthetic peptides, which may be templates for therapeutics development.
- 8 August 2023
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (15)
Open AccessAn LRP1-binding motif in cellular prion protein replicates cell-signaling activities of the full-length protein
Low-density lipoprotein receptor-related protein-1 (LRP1) functions as a receptor for nonpathogenic cellular prion protein (PrP C ), which is released from cells by ADAM (a disintegrin and metalloproteinase domain) proteases or in extracellular vesicles. This interaction activates cell signaling and attenuates inflammatory responses. We screened 14-mer PrP C -derived peptides and identified a putative LRP1 recognition motif in the PrP C sequence spanning residues 98–111. A synthetic peptide (P3) corresponding to this region replicated the cell-signaling and biological activities of full-length shed PrP C . P3 blocked LPS-elicited cytokine expression in macrophages and microglia and rescued the heightened sensitivity to LPS in mice in which the PrP C gene ( Prnp ) had been deleted. P3 activated ERK1/2 and induced neurite outgrowth in PC12 cells. The response to P3 required LRP1 and the NMDA receptor and was blocked by the PrP C -specific antibody, POM2. P3 has Lys residues, which are typically necessary for LRP1 binding. Converting Lys 100 and Lys 103 into Ala eliminated the activity of P3, suggesting that these residues are essential in the LRP1-binding motif. A P3 derivative in which Lys 105 and Lys 109 were converted into Ala retained activity. We conclude that the biological activities of shed PrP C , attributed to interaction with LRP1, are retained in synthetic peptides, which may be templates for therapeutics development.
- 22 March 2023
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 124 (5) , 743-752
An antibody that targets cell‐surface glucose‐regulated protein‐78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages
Glucose‐regulated protein‐78 (Grp78) is an endoplasmic reticulum chaperone, which is secreted by cells and associates with cell surfaces, where it functions as a receptor for activated α2‐macroglobulin (α2M) and tissue‐type plasminogen activator (tPA). In macrophages, α2M and tPA also bind to the transmembrane receptor, LDL receptor‐related protein‐1 (LRP1), activating a cell‐signaling receptor assembly that includes the NMDA receptor (NMDA‐R) to suppress innate immunity. Herein, we demonstrate that an antibody targeting Grp78 (N88) inhibits NFκB activation and expression of proinflammatory cytokines in bone marrow‐derived macrophages (BMDMs) treated with the toll‐like receptor‐4 (TLR4) ligand, lipopolysaccharide, or with agonists that activate TLR2, TLR7, or TLR9. Pharmacologic inhibition of the NMDA‐R or deletion of the gene encoding LRP1 (Lrp1) in BMDMs neutralizes the activity of N88. The fibrinolysis protease inhibitor, plasminogen activator inhibitor‐1 (PAI1), has been implicated in diverse diseases including metabolic syndrome, cardiovascular disease, and type 2 diabetes. Deletion ofLrp1independently increased expression of PAI1 and PAI2 in BMDMs, as did treatment of wild‐type BMDMs with TLR agonists. tPA, α2M, and N88 inhibited expression of PAI1 and PAI2 in BMDMs treated with TLR‐activating agents. Inhibiting Src family kinases blocked the ability of both N88 and tPA to function as anti‐inflammatory agents, suggesting that the cell‐signaling pathway activated by tPA and N88, downstream of LRP1 and the NMDA‐R, may be equivalent. We conclude that targeting cell‐surface Grp78 may be effective in suppressing innate immunity by a mechanism that requires LRP1 and the NMDA‐R.
- 22 March 2023
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 124 (5) , 743-752
An antibody that targets cell‐surface glucose‐regulated protein‐78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages
Glucose‐regulated protein‐78 (Grp78) is an endoplasmic reticulum chaperone, which is secreted by cells and associates with cell surfaces, where it functions as a receptor for activated α2‐macroglobulin (α2M) and tissue‐type plasminogen activator (tPA). In macrophages, α2M and tPA also bind to the transmembrane receptor, LDL receptor‐related protein‐1 (LRP1), activating a cell‐signaling receptor assembly that includes the NMDA receptor (NMDA‐R) to suppress innate immunity. Herein, we demonstrate that an antibody targeting Grp78 (N88) inhibits NFκB activation and expression of proinflammatory cytokines in bone marrow‐derived macrophages (BMDMs) treated with the toll‐like receptor‐4 (TLR4) ligand, lipopolysaccharide, or with agonists that activate TLR2, TLR7, or TLR9. Pharmacologic inhibition of the NMDA‐R or deletion of the gene encoding LRP1 (Lrp1) in BMDMs neutralizes the activity of N88. The fibrinolysis protease inhibitor, plasminogen activator inhibitor‐1 (PAI1), has been implicated in diverse diseases including metabolic syndrome, cardiovascular disease, and type 2 diabetes. Deletion ofLrp1independently increased expression of PAI1 and PAI2 in BMDMs, as did treatment of wild‐type BMDMs with TLR agonists. tPA, α2M, and N88 inhibited expression of PAI1 and PAI2 in BMDMs treated with TLR‐activating agents. Inhibiting Src family kinases blocked the ability of both N88 and tPA to function as anti‐inflammatory agents, suggesting that the cell‐signaling pathway activated by tPA and N88, downstream of LRP1 and the NMDA‐R, may be equivalent. We conclude that targeting cell‐surface Grp78 may be effective in suppressing innate immunity by a mechanism that requires LRP1 and the NMDA‐R.
- Open Access
- 25 January 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (3) , 101642
Cellular prion protein in human plasma–derived extracellular vesicles promotes neurite outgrowth via the NMDA receptor–LRP1 receptor system
- 25 January 2022
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 298 (3) , 101642
Open AccessCellular prion protein in human plasma–derived extracellular vesicles promotes neurite outgrowth via the NMDA receptor–LRP1 receptor system
- Open Access
- 22 November 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (1) , 85-96
A Soluble PrPC Derivative and Membrane-Anchored PrPC in Extracellular Vesicles Attenuate Innate Immunity by Engaging the NMDA-R/LRP1 Receptor Complex
Nonpathogenic cellular prion protein (PrPC) demonstrates anti-inflammatory activity; however, the responsible mechanisms are incompletely defined. PrPC exists as a GPI-anchored membrane protein in diverse cells; however, PrPC may be released from cells by ADAM proteases or when packaged into extracellular vesicles (EVs). In this study, we show that a soluble derivative of PrPC (S-PrP) counteracts inflammatory responses triggered by pattern recognition receptors in macrophages, including TLR2, TLR4, TLR7, TLR9, NOD1, and NOD2. S-PrP also significantly attenuates the toxicity of LPS in mice. The response of macrophages to S-PrP is mediated by a receptor assembly that includes the N-methyl-d-aspartate receptor (NMDA-R) and low-density lipoprotein receptor–related protein-1 (LRP1). PrPC was identified in EVs isolated from human plasma. These EVs replicated the activity of S-PrP, inhibiting cytokine expression and IκBα phosphorylation in LPS-treated macrophages. The effects of plasma EVs on LPS-treated macrophages were blocked by PrPC-specific Ab, by antagonists of LRP1 and the NMDA-R, by deleting Lrp1 in macrophages, and by inhibiting Src family kinases. Phosphatidylinositol-specific phospholipase C dissociated the LPS-regulatory activity from EVs, rendering the EVs inactive as LPS inhibitors. The LPS-regulatory activity that was lost from phosphatidylinositol-specific phospholipase C–treated EVs was recovered in solution. Collectively, these results demonstrate that GPI-anchored PrPC is the essential EV component required for the observed immune regulatory activity of human plasma EVs. S-PrP and EV-associated PrPC regulate innate immunity by engaging the NMDA-R/LRP1 receptor system in macrophages. The scope of pattern recognition receptors antagonized by S-PrP suggests that released forms of PrPC may have broad anti-inflammatory activity.
- 22 November 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 208 (1) , 85-96
Open AccessA Soluble PrPC Derivative and Membrane-Anchored PrPC in Extracellular Vesicles Attenuate Innate Immunity by Engaging the NMDA-R/LRP1 Receptor Complex
Nonpathogenic cellular prion protein (PrPC) demonstrates anti-inflammatory activity; however, the responsible mechanisms are incompletely defined. PrPC exists as a GPI-anchored membrane protein in diverse cells; however, PrPC may be released from cells by ADAM proteases or when packaged into extracellular vesicles (EVs). In this study, we show that a soluble derivative of PrPC (S-PrP) counteracts inflammatory responses triggered by pattern recognition receptors in macrophages, including TLR2, TLR4, TLR7, TLR9, NOD1, and NOD2. S-PrP also significantly attenuates the toxicity of LPS in mice. The response of macrophages to S-PrP is mediated by a receptor assembly that includes the N-methyl-d-aspartate receptor (NMDA-R) and low-density lipoprotein receptor–related protein-1 (LRP1). PrPC was identified in EVs isolated from human plasma. These EVs replicated the activity of S-PrP, inhibiting cytokine expression and IκBα phosphorylation in LPS-treated macrophages. The effects of plasma EVs on LPS-treated macrophages were blocked by PrPC-specific Ab, by antagonists of LRP1 and the NMDA-R, by deleting Lrp1 in macrophages, and by inhibiting Src family kinases. Phosphatidylinositol-specific phospholipase C dissociated the LPS-regulatory activity from EVs, rendering the EVs inactive as LPS inhibitors. The LPS-regulatory activity that was lost from phosphatidylinositol-specific phospholipase C–treated EVs was recovered in solution. Collectively, these results demonstrate that GPI-anchored PrPC is the essential EV component required for the observed immune regulatory activity of human plasma EVs. S-PrP and EV-associated PrPC regulate innate immunity by engaging the NMDA-R/LRP1 receptor system in macrophages. The scope of pattern recognition receptors antagonized by S-PrP suggests that released forms of PrPC may have broad anti-inflammatory activity.
- 1 October 2021
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 321 (4) , C721-C734
Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation
Tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) are serine proteases and major activators of fibrinolysis in mammalian systems. Because fibrinolysis is an essential component of the response to tissue injury, diverse cells, including cells that participate in the response to injury, have evolved receptor systems to detect tPA and uPA and initiate appropriate cell-signaling responses. Formation of functional receptor systems for the plasminogen activators requires assembly of diverse plasma membrane proteins, including but not limited to: the urokinase receptor (uPAR); integrins; N-formyl peptide receptor-2 (FPR2), receptor tyrosine kinases (RTKs), the N-methyl-d-aspartate receptor (NMDA-R), and low-density lipoprotein receptor-related protein-1 (LRP1). The cell-signaling responses elicited by tPA and uPA impact diverse aspects of cell physiology. This review describes rapidly evolving knowledge regarding the structure and function of plasminogen activator receptor assemblies. How these receptor assemblies regulate innate immunity and inflammation is then considered.
- 1 October 2021
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 321 (4) , C721-C734
Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation
Tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA) are serine proteases and major activators of fibrinolysis in mammalian systems. Because fibrinolysis is an essential component of the response to tissue injury, diverse cells, including cells that participate in the response to injury, have evolved receptor systems to detect tPA and uPA and initiate appropriate cell-signaling responses. Formation of functional receptor systems for the plasminogen activators requires assembly of diverse plasma membrane proteins, including but not limited to: the urokinase receptor (uPAR); integrins; N-formyl peptide receptor-2 (FPR2), receptor tyrosine kinases (RTKs), the N-methyl-d-aspartate receptor (NMDA-R), and low-density lipoprotein receptor-related protein-1 (LRP1). The cell-signaling responses elicited by tPA and uPA impact diverse aspects of cell physiology. This review describes rapidly evolving knowledge regarding the structure and function of plasminogen activator receptor assemblies. How these receptor assemblies regulate innate immunity and inflammation is then considered.
- 17 January 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (4) , 590-601
Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease
- 17 January 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (4) , 590-601
Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease
- Open Access
- 1 October 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (41) , 14178-14188
A soluble derivative of PrPC activates cell-signaling and regulates cell physiology through LRP1 and the NMDA receptor
- 1 October 2020
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 295 (41) , 14178-14188
Open AccessA soluble derivative of PrPC activates cell-signaling and regulates cell physiology through LRP1 and the NMDA receptor